| Tying Odysseus to the mast: Evidence from a commitment savings product in the Philippines N Ashraf, D Karlan, W Yin The Quarterly Journal of Economics 121 (2), 635-672, 2006 | 2010 | 2006 |
| Female empowerment: Impact of a commitment savings product in the Philippines N Ashraf, D Karlan, W Yin World development 38 (3), 333-344, 2010 | 804 | 2010 |
| Poverty alleviation through geographic targeting: How much does disaggregation help? C Elbers, T Fujii, P Lanjouw, B Özler, W Yin Journal of Development Economics 83 (1), 198-213, 2007 | 304 | 2007 |
| The effect of the Medicare Part D prescription benefit on drug utilization and expenditures W Yin, A Basu, JX Zhang, A Rabbani, DO Meltzer, GC Alexander Annals of internal medicine 148 (3), 169-177, 2008 | 251 | 2008 |
| Market incentives and pharmaceutical innovation W Yin Journal of Health Economics 27 (4), 1060-1077, 2008 | 201 | 2008 |
| Deposit collectors N Ashraf, D Karlan, W Yin The BE Journal of Economic Analysis & Policy 6 (2), 0000102202153806371483, 2006 | 176 | 2006 |
| A review of commitment savings products in development countries N Ashraf, N Gons, DS Karlan, W Yin ERD working paper series, 2003 | 128 | 2003 |
| Medical debt in the US, 2009-2020 R Kluender, N Mahoney, F Wong, W Yin JAMA 326 (3), 250-256, 2021 | 85 | 2021 |
| R&D policy, agency costs and innovation in personalized medicine W Yin Journal of health economics 28 (5), 950-962, 2009 | 74 | 2009 |
| The market for high-quality medicine: retail chain entry and drug quality in India D Bennett, W Yin Review of Economics and Statistics 101 (1), 76-90, 2019 | 67* | 2019 |
| Impact of Medicare Part D on Medicare–Medicaid dual‐eligible beneficiaries' prescription utilization and expenditures A Basu, W Yin, GC Alexander Health services research 45 (1), 133-151, 2010 | 65 | 2010 |
| Environmental regulation and industrial performance: Evidence from unexpected externalities in China GH Jefferson, S Tanaka, W Yin Available at SSRN 2216220, 2013 | 60 | 2013 |
| The role of behavioral frictions in health insurance marketplace enrollment and risk: Evidence from a field experiment R Domurat, I Menashe, W Yin American Economic Review 111 (5), 1549-1574, 2021 | 55 | 2021 |
| Insurers’ negotiating leverage and the external effects of Medicare part D D Lakdawalla, W Yin Review of Economics and Statistics 97 (2), 314-331, 2015 | 54* | 2015 |
| Household decision making and savings impacts: further evidence from a commitment savings product in the Philippines N Ashraf, DS Karlan, W Yin Yale University Economic Growth Center Discussion Paper, 2006 | 53 | 2006 |
| Valuing health technologies at NICE: recommendations for improved incorporation of treatment value in HTA D Goldman, D Lakdawalla, TJ Philipson, W Yin Health Econ 19 (10), 1109-1116, 2010 | 52 | 2010 |
| Economic burden of multiple myeloma among patients in successive lines of therapy in the United States JP MacEwan, K Batt, W Yin, D Peneva, S Sison, S Vine, C Chen Leukemia & lymphoma 59 (4), 941-949, 2018 | 44 | 2018 |
| Environmental regulation and industrial performance: Evidence from China S Tanaka, W Yin, GH Jefferson Work. Pap., Tufts Univ., Medford, MA, 2014 | 42 | 2014 |
| The impact of the Medicare Part D prescription benefit on generic drug use JX Zhang, W Yin, SX Sun, GC Alexander Journal of general internal medicine 23, 1673-1678, 2008 | 41 | 2008 |
| Evaluating cost benefits of combination therapies for advanced melanoma IS Jensen, E Zacherle, CM Blanchette, J Zhang, W Yin Drugs in Context 5, 2016 | 25 | 2016 |
